Technical Analysis for EGRX - Eagle Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | -10.50% | |
| Oversold Stochastic | Weakness | -10.50% | |
| 1,2,3 Retracement Bearish | Bearish Swing Setup | 19.33% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 19.33% | |
| NR7 | Range Contraction | 19.33% | |
| Wide Bands | Range Expansion | 19.33% | |
| Oversold Stochastic | Weakness | 19.33% | |
| 1,2,3 Retracement Bearish | Bearish Swing Setup | 19.33% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 19.33% | |
| Wide Bands | Range Expansion | 19.33% |
Free Daily (Stock) Chart Reading
- Earnings date: 11/12/2024
Eagle Pharmaceuticals, Inc. Description
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was founded in 2007 and is based in Woodcliff Lake, New Jersey.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Pharmaceutical Lymphoma Small Cell Lung Cancer Stroke Lung Cancer Toxicology Organic Chemistry Chronic Lymphocytic Leukemia Lymphocytic Leukemia Angioplasty Heparin Percutaneous Thrombocytopenia Treatment Of Chronic Lymphocytic Leukemia Nitrogen Mustards
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 14.78 |
| 52 Week Low | 0.1 |
| Average Volume | 189,567 |
| 200-Day Moving Average | 4.69 |
| 50-Day Moving Average | 3.68 |
| 20-Day Moving Average | 2.65 |
| 10-Day Moving Average | 1.26 |
| Average True Range | 0.53 |
| RSI (14) | 26.47 |
| ADX | 39.91 |
| +DI | 9.31 |
| -DI | 37.59 |
| Chandelier Exit (Long, 3 ATRs) | 3.27 |
| Chandelier Exit (Short, 3 ATRs) | 1.70 |
| Upper Bollinger Bands | 5.74 |
| Lower Bollinger Band | -0.44 |
| Percent B (%b) | 0.2 |
| BandWidth | 233.12 |
| MACD Line | -0.99 |
| MACD Signal Line | -0.78 |
| MACD Histogram | -0.2123 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.55 | ||||
| Resistance 3 (R3) | 1.57 | 1.33 | 1.43 | ||
| Resistance 2 (R2) | 1.33 | 1.14 | 1.33 | 1.38 | |
| Resistance 1 (R1) | 1.07 | 1.02 | 1.20 | 1.05 | 1.34 |
| Pivot Point | 0.83 | 0.83 | 0.90 | 0.83 | 0.83 |
| Support 1 (S1) | 0.57 | 0.64 | 0.70 | 0.55 | 0.26 |
| Support 2 (S2) | 0.33 | 0.52 | 0.33 | 0.22 | |
| Support 3 (S3) | 0.07 | 0.33 | 0.18 | ||
| Support 4 (S4) | 0.05 |
